VICTOR RIVERA to Male
This is a "connection" page, showing publications VICTOR RIVERA has written about Male.
Connection Strength
0.257
-
Contribution of the use of basic telemedicine tools to the care of children and adolescents with juvenile idiopathic arthritis at the Puerto Montt Hospital, Chile. Rev Chil Pediatr. 2018 Feb; 89(1):59-66.
Score: 0.022
-
Multiple sclerosis care in Latin America. Neurology. 2014 May 06; 82(18):1660-1.
Score: 0.017
-
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol. 2013 Jul 11; 13:80.
Score: 0.016
-
Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012 Aug; 41(2):425-32.
Score: 0.015
-
Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens. Mol Cancer Ther. 2011 Jun; 10(6):1059-71.
Score: 0.014
-
A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009 Jan; 48(1):49-52.
Score: 0.011
-
Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study. Br J Haematol. 2026 Jul; 209(1):107-115.
Score: 0.010
-
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2005 Jun 28; 64(12):2163.
Score: 0.009
-
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
Score: 0.009
-
Hemorrhage Sites and Mitigation Strategies After Pancreaticoduodenectomy. JAMA Surg. 2024 08 01; 159(8):891-899.
Score: 0.009
-
[Pharmacologic treatment of multiple sclerosis]. Rev Neurol. 2001 Feb 1-15; 32(3):285-8.
Score: 0.007
-
[The treatment of multiple sclerosis with beta-interferon 1a]. Rev Neurol. 2000 Sep 1-15; 31(5):470-1.
Score: 0.007
-
Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J. 2020 05 26; 10(5):61.
Score: 0.006
-
Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8657-62.
Score: 0.006
-
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018 07 26; 132(4):393-404.
Score: 0.005
-
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
Score: 0.005
-
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016 05; 17(5):612-21.
Score: 0.005
-
Neurologic deficit in patients at high risk with thoracoabdominal aortic aneurysms: the role of cerebral spinal fluid drainage and distal aortic perfusion. J Vasc Surg. 1994 Sep; 20(3):434-44; discussion 442-3.
Score: 0.004
-
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov 07; 369(19):1783-96.
Score: 0.004
-
Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis. Acta Neurol Belg. 2013 Dec; 113(4):415-20.
Score: 0.004
-
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol. 2013 Apr; 24(4):1104-11.
Score: 0.004
-
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012 Nov 29; 367(22):2075-88.
Score: 0.004
-
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012 01 01; 30(1):78-84.
Score: 0.004
-
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
Score: 0.004
-
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011 Nov 10; 118(19):5250-4.
Score: 0.003
-
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010 Oct 20; 28(30):4554-61.
Score: 0.003
-
Is the Puerto Rican racer, Alsophis portoricensis, really harmless? A case report series. Wilderness Environ Med. 2010 Dec; 21(4):353-6.
Score: 0.003
-
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol. 2010 Jun; 21(6):1315-1322.
Score: 0.003
-
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 01; 14(9):2756-62.
Score: 0.003
-
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008 Jan 20; 26(3):361-7.
Score: 0.003
-
Multiple sclerosis. Is the mystery beginning to unfold? Postgrad Med. 1986 Jun; 79(8):217-32.
Score: 0.002
-
Narcolepsy following cerebral hypoxic ischemia. Ann Neurol. 1986 May; 19(5):505-8.
Score: 0.002
-
Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39.
Score: 0.002
-
Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol. 2004 Apr 15; 172(8):5120-7.
Score: 0.002
-
Ex vivo detection of myelin basic protein-reactive T cells in multiple sclerosis and controls using specific TCR oligonucleotide probes. Eur J Immunol. 2004 Mar; 34(3):870-881.
Score: 0.002
-
Human anti-idiotypic T cells induced by TCR peptides corresponding to a common CDR3 sequence motif in myelin basic protein-reactive T cells. Int Immunol. 2003 Sep; 15(9):1073-80.
Score: 0.002
-
Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis. J Neuroimmunol. 2003 Apr; 137(1-2):144-53.
Score: 0.002
-
Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003 Feb; 53(2):189-97.
Score: 0.002
-
Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis. Immunology. 2002 Dec; 107(4):403-10.
Score: 0.002
-
Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002 May; 8(3):237-42.
Score: 0.002
-
Regulatory effects of estriol on T cell migration and cytokine profile: inhibition of transcription factor NF-kappa B. J Neuroimmunol. 2002 Mar; 124(1-2):106-14.
Score: 0.002
-
T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol. 2002 Feb; 249(2):212-8.
Score: 0.002
-
Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals. Eur J Immunol. 2001 Mar; 31(3):907-17.
Score: 0.002
-
Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol. 2001 Jan 01; 112(1-2):174-80.
Score: 0.002
-
Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol. 2000 Dec; 12(12):1641-50.
Score: 0.002
-
Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain. 2000 Sep; 123 ( Pt 9):1874-82.
Score: 0.002
-
Immunoregulation and blocking antibodies induced by interferon beta treatment in MS. Neurology. 2000 Aug 08; 55(3):397-404.
Score: 0.002
-
Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness. Arch Neurol. 1980 Apr; 37(4):201-3.
Score: 0.002
-
Hereditary myoclonus and progressive distal muscular atrophy. Ann Neurol. 1979 Sep; 6(3):227-31.
Score: 0.002
-
T cell responses to myelin basic protein in patients with spinal cord injury and multiple sclerosis. J Neuroimmunol. 1999 Aug 03; 98(2):201-7.
Score: 0.002
-
The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol. 1998 Mar; 159(3):972-6.
Score: 0.001
-
Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJR Am J Roentgenol. 1990 Dec; 155(6):1303-7.
Score: 0.001
-
Spinal cord ischemia after resection of thoracoabdominal aortic aneurysms: MR findings in 24 patients. AJNR Am J Neuroradiol. 1990 Sep-Oct; 11(5):987-91.
Score: 0.001